Table 2

Summary of clinical criteria for initiation of a first bDMARD for European countries with at least one biologic reimbursed (n=36)

Minimal clinical requirements for initiation of a bDMARD
Disease durationDAS28 levelNumber of sDMARDs to be failed
N (%)CountriesScore*N (%)CountriesScore*N (%)CountriesScore*
No requirement23 (64%)AL, AT, BE, DK, FI, FR, DE,GR, IS, IE, LV, LT, LU, MK, NL, NO, PT, RO, SL, ES, SE, CH and TR1No requirement5 (14%)DE, IE, LU, MT and CH2<214 (39%)AT, CZ, FR, DE, IS, IE, IT, LU, NO, PT, SK, ES, SE and CH2
<6 months12 (33%)BG, HR, CY, CZ, EE, HU, IT, MT, ME, RS, SK and UK0Up to and including 3.211 (31%)AT, DK, FI, IS, IT, LV, NL, NO, PT, SK and ES1218 (50%)AL, BE, BG, HR, CY, DK, GR, HU, LT, MK, MT, ME, NL, PL, RO, RS, SL and UK1
≥6 months1 (3%)PL0Above 3.220 (56%)AL, BE, BG, HR, CY, CZ, EE, FR, GR, HU, LT, MK, ME, PL, RO, RS, SL, SE, TR and UK0>24 (11%)EE, FI, LV and TR0
  • *Score is the contribution to the composite score for restrictiveness of clinical criteria for initiation of a biologic disease-modifying antirheumatic drugs (bDMARD). DAS28, disease activity score with 28-joint assessment; DMARD, disease-modifying antirheumatic drug; sDMARDs, synthetic disease-modifying antirheumatic drugs.

  • AL, Albania; AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CY, Cyprus; CZ, Czech Republic; DE, Germany; DK, Denmark; DK, Denmark; EE, Estonia; ES, Spain; FI, Finland; FR, France; GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; IS, Iceland; IT, Italy; LT, Lithuania; LU, Luxemburg; LV, Latvia; ME, Montenegro; MK, Macedonia; MT, Malta; NL, the Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RS, Serbia; SE, Sweden; SK, Slovakia; SL, Slovenia; TR, Turkey; UK, United Kingdom.